These Cavas Offer Champagne Quality at a Fraction of the Cost
I found that description so promising, I bought the wine—which tasted toasty but cheap. However, several other examples of this Spanish sparkling wine that I purchased for this column definitely merited praise. This was especially true of the pricier wines from smaller Cava estates.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Chelsea's Xavi Simons deal in danger! RB Leipzig refusing to take back Blues outcasts in deal as talks continue for Dutch forward
Chelsea's swap deal for Simons hits major roadblock RB Leipzig demand £60m — reject all swap offers Agent Ali Barat working to unlock transfer breakthrough Follow GOAL on WhatsApp! 🟢📱 WHAT HAPPENED? As per The Sun, Chelsea have offered multiple players in exchange for Simons, including Armando Broja and Carney Chukwuemeka. However, RB Leipzig are only interested in a cash deal worth £60m ($79m) for the Dutch international. Agent Ali Barat, who has good relations with Chelsea, is said to be working behind the scenes to try and rescue the transfer. THE BIGGER PICTURE Simons joined RB Leipzig permanently from Paris Saint-Germain in January after a loan stint with the Bundesliga side. His decision to leave comes after Leipzig failed to secure Champions League qualification. Chelsea, meanwhile, are making other moves in the market, sending Kendry Paez, Mike Penders, and Marc Guiu out on loan to open up the budget to sign Simons. DID YOU KNOW? RB Leipzig paid a club-record £43m for Simons, with add-ons potentially raising the deal to £70m. As such, Die Roten Bullen are not ready to sell the Dutchman for less than £60m. The Blues still view Simons as a priority target for the summer, despite the recent setback. WHAT NEXT FOR SIMONS? Negotiations are expected to continue as Chelsea weigh up whether to meet RB Leipzig's asking price for Simons. The Blues could return with a fresh offer later in the window if Barat finds a breakthrough. Meanwhile, other midfield options may be explored as a backup plan.
Yahoo
an hour ago
- Yahoo
Jim Cramer Believes CAVA is a 'Great Long-Term Position' But Suggests Waiting for More Dip
CAVA Group, Inc. (NYSE:CAVA) is one of the stocks Jim Cramer shared insights on. Noting the stock's recent ups and downs, a caller asked if there is any reason for the 'wild swing'. Here's what Cramer had to say in response: 'Yes, yes. It's what I call, it's a terrible trader, and there's been these big chunks that come for sale, and you have to just close your eyes. You can't watch the trading because it's very, very unnerving, and you want to hit it on a real dip, which you don't have right now because it was down to 70 earlier this year. Wait for more of a dip for Cava, but I think it's a great long-term position.' Stock market data showing an upward trajectory. Photo by Burak The Weekender on Pexels CAVA (NYSE:CAVA) operates restaurants under the CAVA brand and provides a range of food products like dips, spreads, and dressings. The company sells its products through grocery stores, along with online and mobile ordering. While we acknowledge the potential of CAVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
Proto Labs Inc (PRLB) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...
Revenue: $135.1 million, a company record, up 6.5% year over year in constant currencies, and up 7% sequentially. CNC Machining Revenue: Grew 20% over the prior year, with a 30% increase in the US. Injection Molding Revenue: Declined 4% year over year. 3D Printing Revenue: Down 1% year over year. Sheet Metal Revenue: Grew 9% year over year. US Revenue: Grew 12% year over year. Europe Revenue: Declined 15% in constant currencies. Non-GAAP Gross Margin: 44.8%, flat sequentially, down 90 basis points year over year. Non-GAAP Operating Expenses: Increased $2.7 million, up 6% consistent with revenue. Adjusted EBITDA: $19.7 million, or 14.6% of revenue. Non-GAAP Earnings Per Share: $0.41, above guidance range, up $0.08 sequentially, and up $0.03 year over year. Cash from Operations: $10.6 million generated during the second quarter. Share Repurchases: $3.1 million returned to shareholders. Cash and Investments: $123.2 million on balance sheet with zero debt. Q3 2025 Revenue Guidance: Expected between $130 million and $138 million, implying 6% growth year over year in constant currencies. Q3 2025 Non-GAAP EPS Guidance: Expected between $0.35 and $0.43. Warning! GuruFocus has detected 7 Warning Signs with PRLB. Release Date: July 31, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Proto Labs Inc (NYSE:PRLB) delivered record revenue of $135.1 million in the second quarter, exceeding expectations. The company saw a 44% growth in customers utilizing their combined offer over the trailing 12 months. Revenue per customer increased by 11% year over year, indicating strong customer engagement. The metal 3D Printing service in Raleigh, North Carolina received ISO 13,485 certification, enhancing credibility in the medical device manufacturing sector. Proto Labs Inc (NYSE:PRLB) continues to generate healthy cash flows, allowing for ongoing investments in growth and innovation. Negative Points Injection Molding revenue declined by 4% year over year, with noted weakness in the medical sector. 3D Printing revenue was down 1% year over year, reflecting continued weakness in prototyping. European revenue declined by 15% in constant currencies, indicating challenges in the region. Tariffs and changing trade policies created short-term margin pressures, impacting profitability. Gross margin was down 90 basis points year over year, driven by higher growth in network revenue and lower US network margins due to tariffs. Q & A Highlights Q: Can you elaborate on the strength you're seeing in CNC, particularly in terms of growth across the factory and network? A: Daniel Schumacher, CFO: We are experiencing similar growth in both the factory and the network, with a 30% CNC growth in the US driving the overall 20% growth for the company. Suresh Krishna, CEO: We've grown revenues with larger accounts due to our go-to-market reorganization, and our production teams have shown agility in responding to customer needs. Q: Is the CNC work leaning more towards production or prototyping? A: Daniel Schumacher, CFO: It is a combination of both production and prototyping. We don't provide a specific split, but both contribute to our revenue growth. Q: Can you provide more details on the Injection Molding business and the factors affecting its performance? A: Daniel Schumacher, CFO: The network is a small portion of our Injection Molding business, with most of it through the factory. We saw some larger production orders last year, particularly in automotive, which impacted year-over-year comparisons. Currently, we are seeing weakness in the medical sector, but we continue to innovate and add capabilities to drive future production growth. Q: What excites you about joining Proto Labs, and what are your initial observations? A: Suresh Krishna, CEO: I'm excited about the opportunity to reaccelerate growth. My focus is on listening to employees, customers, and partners to remove friction and identify future opportunities. I believe there is significant potential to enhance customer and employee experiences. Q: Can you explain the impact of tariffs on gross margins and how it was addressed? A: Daniel Schumacher, CFO: Tariffs impacted our US network margins, particularly on aluminum and steel. We adjusted pricing and fulfillment strategies, and by June, margins returned to normal. The impact was due to a backlog priced at different assumptions, but adjustments have since stabilized margins. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
